VERICEL CORPORATION Income (Loss) from Continuing Operations before Income Taxes, Domestic
VERICEL CORPORATION (VCEL) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $17.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- VERICEL CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $17.47M, a 65.13% increase from fiscal 2024.
- VERICEL CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $10.58M.
- VERICEL CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$2.38M.
- VERICEL CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$15.91M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $17.47M 10-K · filed 2026-02-26 |
| 2024-12-31 | $10.58M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$2.38M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$15.91M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$7.37M 10-K · filed 2024-02-29 |
| 2020-12-31 | $2.77M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |